RGCC Q&A

Oncotrace is intended for monitoring patients with a confirmed cancer diagnosis or reactive Onco-D-Clare results. It is not designed as a general screening tool, as prior cancer-specific information is required for accurate test performance.

It provides a detailed profile of circulating tumour cells (CTCs), including their phenotype and stemness characteristics, using both negative and positive selection. This allows clinicians to evaluate disease progression and response to treatment with precision.

Onco-D-Clare identifies gene expression patterns related to specific cancer types. This information helps the lab choose appropriate CTC culture media, enhancing the diagnostic reliability of Oncotrace.

Unlike standard tests that only use EpCAM-based positive selection, RGCC also applies negative selection to exclude non-cancerous cells. This dual approach improves the detection of diverse CTC populations, including those undergoing epithelial-to-mesenchymal transition (EMT).

CTCs from different cancer types have unique biological behaviors and growth needs. Onco-D-Clare’s profiling enables RGCC to use tailored media, ensuring better culture success and analysis accuracy.

• Onco-D-Clare: 92.4% sensitivity and 94.78% specificity
• Oncotrace: 86.2% sensitivity and 83.9% specificity
  These figures are based on real patient data, not artificially spiked samples.

It signals the presence of gene expression patterns commonly associated with malignancy. However, it is not diagnostic and should be followed up with confirmatory testing like Oncotrace or imaging.

The test uses robust machine learning to differentiate cancer signals from those caused by inflammation, infection, or immune system activation—enhancing its reliability.

RGCC uses real patient samples to measure test sensitivity and specificity, providing results that more accurately reflect clinical conditions compared to tests based on artificially spiked samples.

• A confirmed diagnosis of cancer, OR
• A reactive Onco-D-Clare test result

These prerequisites ensure the test is used in the right clinical context for optimal results.

• Detects microscopic recurrence before symptoms arise
• Allows dynamic, personalized treatment adjustments
• Enables non-invasive, repeated monitoring via blood tests

No. It is a high-level risk assessment tool. A reactive result should prompt further investigations to confirm malignancy, such as CTC testing or imaging.

• CAP (College of American Pathologists)
• CLIA (Clinical Laboratory Improvement Amendments, USA)
• IAS (International Accreditation Service)
  These accreditations confirm RGCC’s commitment to clinical quality, laboratory excellence, and itional standards.